Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
JCR Organizes and Conducts API Plant Tour for Local Residents
Consolidated Financial Results for the Six Months ended September 30, 2025 (FY2025) (Japanese standard)
FY2025 Second Quarter Results Briefing Session Material
Shin Ashida of JCR Pharmaceuticals Named Kansai Regional Representative in EY Entrepreneur of The Year(TM) 2025 Japan
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
Corporate Gavanance Report
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
JCR Pharmaceuticals Unveils New Corporate Tagline, “Life is Rare,” to Mark Its 50th Anniversary
Notice of Personnel Change
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
Notice of Personnel Change
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
JCR Pharmaceuticals Sponsors and Participates in Relay For Life of Ashiya
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
Notice of Organizational and Personnel Changes
Notice of Personnel Change
PHC and JCR GROWJECTOR L Automated Injection Device Wins 2025 Kids Design Award
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis